ALK and non-small cell lung carcinoma: Over the last decade, the therapeutic landscape for ALK‐positive (ALK+) NSCLC has witnessed a paradigm shift, with the advent of ALK‐tyrosine kinase inhibitors (ALK‐TKIs).7, 8